Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?

Published:2022-08-01 Issue:8 Volume:47 Page:1585-1586
ISSN:1365-2230
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Ring Hans Christian¹^ORCID,Frew John W.²,Thyssen Jacob P.¹,Egeberg Alexander¹^ORCID,Thomsen Simon F.¹³^ORCID

Affiliation:

1. Department of Dermato-Venereology and Wound Healing Centre Bispebjerg Hospital Copenhagen Denmark

2. Department of Dermatology Liverpool Hospital Sydney NSW Australia

3. Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark

Funder

Lundbeckfonden

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ced.15232

Reference8 articles.

1. Two phase 3 trials of adalimumab for hidradenitis suppurativa;Kimball;N Engl J Med,2016

2. Drug survival of biologics in patients with hidradenitis suppurativa;Ring;JAMA Dermatol,2022

3. Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients;McPhie;J Cutan Med Surg,2019

4. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls;Ring;JAMA Dermatol,2017

5. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa;Zouboulis;Dermatology,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data;Clinical, Cosmetic and Investigational Dermatology;2023-09

2. The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered;The Lancet;2023-03

3. Tacrolimus ointment may improve the effectiveness of adalimumab in patients with hidradenitis suppurativa: a novel promising treatment;Clinical and Experimental Dermatology;2022-10-01

4. Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’;Clinical and Experimental Dermatology;2022-10-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3